Effect of trastuzumab and lonidamine-loaded lipid nanoparticles (lnp) on her2+ breast cancer

Basit Öğe Kaydı
dc.authorid0000-0002-1423-0435
dc.contributor.authorZurnacı, Fatma Özlem
dc.contributor.authorÖzdatlı Kurtuluş, Şükran
dc.contributor.authorŞengel Türk, Ceyda Tuba
dc.contributor.authorHasçiçek, Canan
dc.contributor.authorGüzel, Mustafa
dc.date.accessioned2024-06-27T11:11:25Z
dc.date.available2024-06-27T11:11:25Z
dc.date.issued2024
dc.departmentİstanbul Medipol Üniversitesi, Eczacılık Fakültesi, Temel Eczacılık Bilimleri Bölümü, Analitik Kimya Ana Bilim Dalı
dc.departmentİstanbul Medipol Üniversitesi, Rektörlük, Sağlık Bilim ve Teknolojileri Araştırma Enstitüsü
dc.departmentİstanbul Medipol Üniversitesi, Sağlık Bilimleri Enstitüsü, Moleküler Tıp ve Biyoteknoloji Ana Bilim Dalı
dc.description.abstractOur study involves inhibition of glycolysis and inhibition of the HER2 pathway, which is highly expressed in many types of cancer. Decreased survival, negative metastasis, and induced apoptosis are expected due to the combined inhibition of these two targets. Trastuzumab was used as the HER2 inhibitor and lonidamine was used as the HK2 inhibitor. Lonidamine (LND) was delivered to cells as hybrid nanoparticles to enhance the effect of lonidamine and make it target specific. Separate cytotoxicity studies were conducted for LND, LND-NP and Tmab. While application of lonidamine alone gave an IC50 value of 124.6 ?M, application in NP reduced the IC50 value to 44.18 ?M. In addition, the combination of Tmab and LND-NP showed synergistic effects compared to treatments alone in other analyses. On the aspect of apoptosis, this combination showed a 14-fold increased apoptosis compared to the control group. This combination therapy can prevent drug resistance. In addition, the hybrid nanoparticle structure used will prevent the formation of toxicity as it will ensure that LND is administered to the body with less repetition. Our study aims to minimize the negative effects of the chemotherapy process by improving it with various variations in future studies.
dc.identifier.citationZurnacı, F. Ö., Özdatlı Kurtuluş, Ş., Şengel Türk, C. T., Hasçiçek, C. ve Güzel, M. (2024). Effect of trastuzumab and lonidamine-loaded lipid nanoparticles (lnp) on her2+ breast cancer. ChemistrySelect, 9(22). http://dx.doi.org/10.1002/slct.202304555
dc.identifier.doi10.1002/slct.202304555
dc.identifier.issn2365-6549
dc.identifier.issue22
dc.identifier.scopus2-s2.0-85195544293
dc.identifier.scopusqualityQ3
dc.identifier.urihttp://dx.doi.org/10.1002/slct.202304555
dc.identifier.urihttps://hdl.handle.net/20.500.12511/12660
dc.identifier.volume9
dc.identifier.wos001240387100001en_US
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.institutionauthorÖzdatlı Kurtuluş, Şükran
dc.institutionauthorGüzel, Mustafa
dc.language.isoen
dc.relation.ispartofChemistrySelecten_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAnd Trastuzumab
dc.subjectApoptosis
dc.subjectCancer
dc.subjectLonidamine
dc.subjectNanoparticle
dc.titleEffect of trastuzumab and lonidamine-loaded lipid nanoparticles (lnp) on her2+ breast cancer
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Özdatlı Kurtuluş-Şükran-2024.pdf
Boyut:
2.88 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Eczacılık Fakültesi Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu